Stock 002262 JIANGSU NHWA PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Jiangsu Nhwa Pharmaceutical Co., LTD

Equities

002262

CNE100000CG8

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
24.81 CNY +3.94% Intraday chart for Jiangsu Nhwa Pharmaceutical Co., LTD +6.57% -8.52%
04-25 Jiangsu Nhwa Pharmaceutical Co., LTD Approves Cash Dividend for 2023 CI
04-19 Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 69% by 2026.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • The company's enterprise value to sales, at 3.68 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JIANGSU NHWA PHARMACEUTICAL CO., LTD Stock Jiangsu Nhwa Pharmaceutical Co., LTD
-8.52% 3.45B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.60% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.62% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.41% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-8.88% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 002262 Stock
  4. Ratings Jiangsu Nhwa Pharmaceutical Co., LTD